Perceived COVID-19 vaccine effectiveness, acceptance, and drivers of vaccination decision-making among the general adult population: A global survey of 20 countries

Roy Rillera Marzo1,2,3, Absar Ahmad4, Md. Saiful Islam5,6, Mohammad Yasir Essar7, Petra Heidler8,9,10, Isabel King11,12, Arulmani Thiyagarajan13, Kittisak Jermsittiparsert14, Karmjana Songwathana15, Delan Ameen Younus16, Radwa Abdullah El-Abasiri17, Burcu Kucuk Bicer18, Nhat Tan Pham19,20, Titik Respati21, Susan Fitrinya22, Erwin Martinez Faller23, Aries Moralidad Baldonado24, Md Arif Billaiah24, Yadanar Aung25,26, Shehu Muhammad Hassan26, Muhammad Mujtaba Asad27, Kareem Ahmed El-Fass28, Sudip Bhattacharyya27, Sunil Shrestha29, Nouran Ameen Elsayed Hamza30,31,32, Pascal Friedmann33, Michael Head34,35, Yulan Lin36,37*, Siyan Yi38,39,40

1 Department of Community Medicine, International Medical School, Management and Science University, Shah Alam, Selangor Darul Ehsan, Malaysia, 2 Department of Community Medicine, Faculty of Medicine, Asia Metropolitan University, Johor Bahru, Malaysia, 3 Global Public Health, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway, Malaysia, 4 Department of Community Medicine, Manipal Tata Medical College, Jamshedpur, Manipal Academy of Higher Education, Manipal, India, 5 Department of Public Health and Informatics, Jahangirnagar University, Savar, Dhaka, Bangladesh, 6 Centre for Advanced Research Excellence in Public Health, Savar, Dhaka, Bangladesh, 7 Kabul University of Medical Sciences, Kabul, Afghanistan, 8 Department of Health Sciences, St. Pölten University of Applied Sciences, St. Pölten, Austria, 9 Department of International Business and Export Management, IMC University of Applied Sciences Krems, Krems an der Donau, Austria, 10 University for Continuing Education Krems, Department for Economy and Health, Krems, Austria, 11 University of the Sunshine Coast, School of Health and Behavioural Sciences, Maroochydore, Australia, 12 Sunshine Coast Health Institute, Sunshine Coast University Hospital and Health Service, Birtinya, Australia, 13 Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology—BIPS, Bremen, Germany, 14 College of Innovative Business and Accountancy, Dhurakij Pundit University, Bangkok, Thailand, 15 Faculty of Economics and Investment, Bangkok University, Bangkok, Thailand, 16 General Directorate for Scientific Research Center, Salahaddin University-erbil, Erbil, Iraq, 17 Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom, 18 Faculty of Medicine, Department of Medical Education and Informatics, Gazi University, Ankara, Turkey, 19 School of Business, International University, Ho Chi Minh City, Vietnam, 20 Vietnam National University, Ho Chi Minh City, Vietnam, 21 Department of Public Health, Faculty of Medicine and Faculty of Graduate Studies, Universitas Islam Bandung, Bandung, Indonesia, 22 Faculty of Medicine, Universitas Islam Bandung, Bandung, Indonesia, 23 Department of Pharmacy, Faculty of Pharmacy, San Pedro College, Davao City, Philippines, 24 College of Nursing, Saint Alexius College, City of Koronadal, Philippines, 25 Faculty of Business, Economics and Social Development, Universiti Malaysia Terengganu, Kuala Terengganu, Malaysia, 26 Medical Statistics Division, Department of Medical Research, Pyin Oo Lwin, Myanmar, 27 Institute for Population and Social Research, Mahidol University, Nakhon Pathom, Thailand, 28 Faculty of Life Sciences, Ahmadu Bello University, Zaria, Nigeria, 29 Education Department, Sukkur IBA University, Sukkur, Pakistan, 30 Department of Pharmacy Practice, College of Clinical Pharmacy, King Faisal University, Al Hassa, Saudi Arabia, 31 Department of Community Medicine, Himalayan Institute of Medical Sciences, Dehradun, India, 32 School of Pharmacy, Monash University Malaysia, Bandar Sunway, Malaysia, 33 Medical Agency for Research and Statistics, Giza, Egypt, 34 Clinical Research Key (CRK-CRO), Nairobi, Kenya, 35 Lumpkin College of Business and Technology, Eastern Illinois University, Charleston, Illinois, United States of America, 36 Clinical Informatics Research Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom, 37 Department of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, Fuzhou, China, 38 Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore, 39 KHANA Center for Population Health Research, Phnom Penh, Cambodia, 40 Center for Global Health Research, Touro University California, Vallejo, California, United States of America

* yulanlin@fjmu.edu.cn
Abstract

Background

Mass vaccination campaigns have significantly reduced the COVID-19 burden. However, vaccine hesitancy has posed significant global concerns. The purpose of this study was to determine the characteristics that influence perceptions of COVID-19 vaccine efficacy, acceptability, hesitancy and decision making to take vaccine among general adult populations in a variety of socioeconomic and cultural contexts.

Methods

Using a snowball sampling approach, we conducted an online cross-sectional study in 20 countries across four continents from February to May 2021.

Results

A total of 10,477 participants were included in the analyses with a mean age of 36±14.3 years. The findings revealed the prevalence of perceptions towards COVID-19 vaccine’s effectiveness (78.8%), acceptance (81.8%), hesitancy (47.2%), and drivers of vaccination decision-making (convenience [73.3%], health providers’ advice [81.8%], and costs [57.0%]). The county-wise distribution included effectiveness (67.8–95.9%; 67.8% in Egypt to 95.9% in Malaysia), acceptance (64.7–96.0%; 64.7% in Australia to 96.0% in Malaysia), hesitancy (31.5–86.0%; 31.5% in Egypt to 86.0% in Vietnam), convenience (49.7–95.7%; 49.7% in Austria to 95.7% in Malaysia), advice (66.1–97.3%; 66.1% in Austria to 97.3% in Malaysia), and costs (16.0–91.3%; 16.0% in Vietnam to 91.3% in Malaysia). In multivariable regression analysis, several socio-demographic characteristics were identified as associated factors of outcome variables including, i) vaccine effectiveness: younger age, male, urban residence, higher education, and higher income; ii) acceptance: younger age, male, urban residence, higher education, married, and higher income; and iii) hesitancy: male, higher education, employed, unmarried, and lower income. Likewise, the factors associated with vaccination decision-making including i) convenience: younger age, urban residence, higher education, married, and lower income; ii) advice: younger age, urban residence, higher education, unemployed/student, married, and medium income; and iii) costs: younger age, higher education, unemployed/student, and lower income.

Conclusions

Most participants believed that vaccination would effectively control and prevent COVID-19, and they would take vaccinations upon availability. Determinant factors found in this study are critical and should be considered as essential elements in developing COVID-19 vaccination campaigns to boost vaccination uptake in the populations.

Author summary

This large-scale multi-country study explores perceived COVID-19 vaccine effectiveness, acceptability, and hesitancy rates and their related factors among the general adult populations from 20 countries. We found that a considerable proportion of the participants has
an intention to receive the COVID-19 vaccine. However, more than half still expressed their hesitancy to receive the vaccines. Countries where the majority of respondents responded that they would accept COVID-19 vaccination included Malaysia (96.0%), Bangladesh (93.6%), and Iraq (91.8%). The majority of the participants from Vietnam (86.0%) and Turkey (74.7%) expressed hesitance to receive COVID-19 vaccine. Perceived vaccine effectiveness ranged from 67.8% in Egypt to 95.9% in Malaysia. The participants believed that convenience, health providers’ advice, and costs of vaccines are important for people to decide whether to accept COVID-19 vaccines. Country of residence, age, sex, level of education, area of residence, marital status, and family economic status were significantly associated with tendency to undergo COVID-19 vaccination and the perception that COVID-19 vaccine decision-making is influenced by convenience. The findings of this study provide useful guidance for tailored interventions to enhance the acceptance of COVID-19 vaccine. Promotional program addressed on detected socioeconomic factors is warranted.

Introduction
The global COVID-19 pandemic has raised imminent public health threats to people across the globe. As it continues spreading, the burden of the cases has become more worrisome. As of September 4, 2021, over 219 million cases have been recorded globally [1]. The epidemic has hit low- and middle-income nations due to relatively weak health care systems in responding to such a public health emergency. The fight against COVID-19 has taken various trends in different parts of the world, with some countries bracing against the third wave of the pandemic [2–5]. South Asian countries like India have experienced colossal impacts of COVID-19, such as oxygen shortage and Delta variant that have exploded the healthcare system in the country [6,7]. Mass vaccination has started to beat the deadly pandemic, but more vaccines are required to supply the large population [8,9]. To prevent further spread, governments worldwide have adopted several prevention measures to contain the pandemic in its early days. However, lessons from the past have revealed that the best tool in preventing any viral epidemic and pandemic is safe and secure vaccines [10].

The World Health Organization (WHO) has approved several vaccines for emergency use against the COVID-19 pandemic. Mass vaccination campaigns across the globe have significantly reduced the burden of cases. However, along with the movements, adverse drug reactions of vaccines, acceptance of vaccines, and hesitancy in populations have raised severe concerns [11,12] and may pose a significant global health threat. Vaccine hesitancy is defined as an individual’s unwillingness to take the vaccines despite their availability [13]. Primary reasons for the willingness to accept vaccination include convenience, complacency, and confidence [14]. Convenience comprises the availability, affordability, and vaccines delivery in a comfortable context. Complacency underscores the low disease risk perception; thus, the need for immunization was deemed unnecessary. Confidence denotes the trust in vaccination safety, effectiveness, and healthcare systems competence [15].

The impact of vaccine hesitancy is threatening the world as it has been listed in the top ten global health threats in 2019 [16,17]. The past rises in measles cases have been linked to vaccine hesitancy as one of the known reasons [18]. To this day, vaccine hesitancy has remained a significant challenge to the world. The COVID-19 pandemic has further reigned the notion of vaccine hesitancy. The rapid vaccine development and media coverage of misinformation are among the reasons behind the rationale of hesitancy towards vaccination [11,19].
Amid the COVID-19 pandemic, the hesitancy in vaccination has taken a surge across the world. This plight has plagued many countries and slowed down the scale of vaccination coverage. To date, many studies have been conducted in different countries and populations to address these concerns [20–24]. Afghanistan, a low-income country with low vaccination coverage, has also witnessed a trend in the hesitancy towards vaccination. Nemat et al. have revealed that over 37% of the population from different provinces in Afghanistan expressed reluctance to get the COVID-19 vaccination [25]. Primary reasons for the unwillingness to get the vaccines were a perception of low vaccine quality and safety and a belief that they have sufficient immunity to combat COVID-19 [25].

A population-based survey in Nigeria during the pandemic peak indicated a high willingness to get the COVID-19 vaccines among the general public [26]. However, 25% of the participants expressed their hesitancy [26]. The primary reasons behind the hesitancy included the perceived unreliability of clinical trials, a belief that they have strong immunity to fight against the disease, and a concern over vaccine safety [26]. These findings emphasize the need for more strategic interventions to understand the barriers better and increase vaccine acceptance across the world.

However, there is a lack of multi-country population-based studies involving different socioeconomic and cultural contexts. A previous study conducted in nine lower- and middle-income countries (LIMCs) reported only COVID-19 prevalence and factors related to vaccine acceptance. Therefore, this large-scale multi-country study explored perceived COVID-19 vaccine effectiveness, acceptability, and hesitancy rates and their related factors among the general adult populations in different socioeconomic and cultural contexts. This study findings will help countries plan for better control of vaccination programs and better prepare for future pandemics.

Methods

Ethics statement

The study was designed and conducted in line with the declaration of Helsinki and was approved by the Asia Metropolitan University Ethics Committee in Malaysia (Ref. No: AMU/MREC/NF/28032020). Respondents were informed that their participation was voluntary, and written consent was implied on the completion of the questionnaire. All participants were aged 18 years or older.

Study design and sampling

An online cross-sectional study was conducted using a google form in Australia, Austria, Bangladesh, Denmark, Egypt, Germany, India, Indonesia, Iraq, Ireland, Malaysia, Myanmar, New Zealand, Nigeria, the Philippines, Scotland, Sri Lanka, Thailand, Turkey, and Vietnam. Data were collected between February 2021 and May 2021 using a snowball sampling approach.

Data collection procedures

We distributed the questionnaire using personal contacts by emails, web-based applications (e.g., WhatsApp, Telegram), and social media (e.g., Facebook, LinkedIn, Twitter, and Instagram). Participants must be aged 18 years or older. They were reminded to respond only once and use a unique identifier to create a single account by settings that allow one response per user. Finally, the confidentiality and privacy of participants’ responses were ensured to minimize potential bias caused by self-reported data.
Data collected using google forms offered an excel format to survey output to analyze the raw data offline. All country’s data in excel were exported to IBM SPSS (version 25). De-identifications were done to secure the safety of respondents, which removed the identifiers like name, email ID, or mobile number that directly or indirectly point to a person.

**Tool development and measures**

We developed the questionnaire through participatory discussion within the research team of participating countries. The COVID-19 related questions were adapted from a previous study [27] conducted on 18 years and above. The questionnaire was completed in less than five minutes. The questionnaire was first designed in English and then translated into the participant countries native languages. It was created to alleviate responder fatigue and was face-validated by experts.

Sociodemographic characteristics of the participants included age (continuous), sex (male/female), place of residence (rural/urban), education (secondary or less/post-secondary/tertiary), employment status (employed/student/unemployed), marital status (ever married/never married), and perceived family economic status (low/medium/high).

Participants’ perception of vaccine effectiveness was assessed by asking whether they agreed that vaccination effectively prevents and controls COVID-19. COVID-19 vaccine acceptance was assessed by asking if the participant would like to get COVID-19 vaccines if they are successfully produced and authorized for use in the future. We also asked whether the participant agreed that convenience, health providers’ advice, and vaccine costs are important factors for deciding whether they should receive the vaccines. To measure vaccine hesitancy, participants were asked whether they would get the vaccine as soon as possible if it become available. The responses of all the questions were binary (yes/no).

**Statistical analyses**

For continuous variables, mean and standard deviation (SD) were calculated. Categorical variables were presented using percentages. In bivariate analyses, we used the Chi-square test to explore associations between categorical variables. Multivariable logistic regression models were constructed to explore factors associated with perceived vaccine effectiveness, acceptance, and drivers of COVID-19 vaccine uptake. The socio-demographic and economic characteristics of the participants were simultaneously included in each model. Adjusted odds ratio (AOR) with 95% confidence intervals (95% CI) were reported. Statistical significance was considered at \( p < 0.05 \).

**Results**

A total of 11,024 participants responded to the survey including 547 incomplete responses. In the final analysis, 10,477 participants were included with a mean age 36 years (SD = 14.28). More than two-thirds (70.8%) were urban residents, 56.7% were female, 47.6% had tertiary education, 63.9% were employed, 53.5% were ever married, and 47.1% reported medium family economic status (Table 1). Thailand had the most significant number of participants (22.6%), followed by Austria (12.9%), Malaysia (12.2%), and Iraq (9.7%).

As shown in Table 2, 78.8% of the participants agreed that vaccination would effectively control and prevent COVID-19, and 81.8% would get COVID-19 vaccines if they are successfully produced and authorized for use in the future. The participants believed that convenience (73.3%), health providers’ advice (81.8%), and costs of vaccines (57.0%) are important for people to decide whether to accept COVID-19 vaccines. About half (52.8%) expressed their hesitancy to receive the vaccines.
Table 1. Study sample characteristics according to residence country (n = 10,477).

|                  | AU  | AT  | BD  | EG  | ID  | IQ  | MY  | MM  | NG  | PH  | TH  | TR  | VN  | Other | Total |
|------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-------|-------|
| Number           | 156 | 1347| 359 | 957 | 522 | 1021| 1283| 301 | 201 | 313 | 2365| 827 | 651 | 174   | 10477 |
| Age              |     |     |     |     |     |     |     |     |     |     |     |     |     |       |       |
| <30 years        | 22  | 141 | 259 | 723 | 329 | 311 | 964 | 128 | 102 | 228 | 791 | 261 | 395 | 42    | 4713  |
| 31–45 years      | 51  | 327 | 500 | 186 | 120 | 327 | 229 | 71  | 90  | 57  | 939 | 140 | 237 | 75    | 3173  |
| 46–60 years      | 42  | 269 | 521 | 40  | 63  | 242 | 71  | 19 | 7.3 | 227 | 579 | 232 | 192 | 50    | 1945  |
| >60 years        | 41  | 263 | 138 | 16  | 10  | 19  | 8   | 1.9| 1.5 | 8.2 | 2.1 | 1.9 | 0.0 | 7.0   | 646.2 |
| Female           | 92  | 59  | 1106| 598 | 376 | 530 | 371 | 17 | 59 | 247 | 1288| 453 | 340 | 121   | 5937  |
| Urban resident    | 94  | 60.3| 786 | 213 | 751 | 310 | 916 | 114 | 269 | 154 | 1602| 687 | 199 | 123   | 7416  |
| Education level  |     |     |     |     |     |     |     |     |     |     |     |     |     |       |       |
| <Secondary       | 58  | 37.2| 483 | 33  | 23  | 278 | 471 | 67 | 4.0 | 8.0 | 492 | 540 | 105 | 37    | 2619  |
| Secondary        | 98  | 62.8| 169 | 58  | 50  | 244 | 424 | 284| 42  | 33  | 705 | 0    | 262 | 51    | 2870  |
| >Secondary       | 0   |   | 0   | 695 | 434 | 244 | 424 | 284| 42  | 33  | 705 | 0    | 262 | 51    | 2870  |
| Currently employed| 134 | 85.9| 1239| 126 | 682 | 188 | 566 | 377 | 261 | 111 | 293 | 293 | 129 | 283   | 1664  |
| Ever married     | 118 | 75.6| 1080| 154 | 325 | 269 | 686 | 328 | 153 | 95  | 1342| 511 | 345 | 124   | 5605  |
| Family economic status |     |     |     |     |     |     |     |     |     |     |     |     |     |       |       |
| Low              | 27  | 17.3| 195 | 92  | 122 | 286 | 290 | 366 | 44  | 26  | 119 | 1045| 137 | 20    | 3016  |
| Medium           | 68  | 43.6| 761 | 138 | 337 | 221 | 557 | 831 | 75  | 18  | 193 | 905 | 413 | 335   | 4933  |
| High             | 61  | 39.1| 391 | 129 | 498 | 174 | 86  | 157 | 1.0 | 415 | 167 | 179 | 73    | 2528  |

Values are the number (%) for categorical variables and mean (SD) for continuous variables. AU: Australia; AT: Austria; BD: Bangladesh; EG: Egypt; ID: Indonesia; IQ: Iraq; MY: Malaysia; MM: Myanmar; NG: Nigeria; PH: Philippines; TH: Thailand; TR: Turkey; VN: Vietnam. Other countries include Canada, China, Germany, India, Ireland, New Zealand, Scotland, Sri-Lanka, and the United Kingdom.

https://doi.org/10.1371/journal.pntd.0010103.t001

Table 3 shows that 95.9% of the participants from Malaysia thought that vaccination would effectively prevent and control COVID-19, followed by those from the Philippines (88.8%) and Vietnam (88.3%). Countries where majority of respondents responded that they would accept COVID-19 vaccination included Malaysia (96.0%), Bangladesh (93.6%), and Iraq (91.8%). Regarding perceived drivers of vaccine uptake decision-making, 95.7% of the participants from Malaysia, 93.0% from the Philippines, and 90.8% from Bangladesh agreed that confidence is an important factor for deciding whether they would receive the vaccines. Majority of the participants from Malaysia (97.3%), the Philippines (93.9%), and Indonesia (93.5%) agreed that health providers’ advice is important in people's decision-making to get the COVID-19 vaccines. Vaccine costs were also believed to be an important factor among the participants from Malaysia (91.3%), the Philippines (81.5%), and Turkey (78.4%). Majority of the participants from Vietnam (86.0%) and Turkey (74.7%) expressed hesitance to receive COVID-19 vaccines.
Table 2. Perceived effectiveness, acceptance, and drivers of COVID-19 vaccine uptake decision-making by country by socio-demographic characteristics ($n = 10,477$).

| Socio-demographic characteristics | Agreed that vaccines are effective to prevent and control COVID-19 | Would accept COVID-19 vaccines when available | Believed that convenience is important for people to decide whether to accept vaccines | Believed that health providers’ advice is important for people to decide whether to accept vaccines | Believed that cost of the vaccines is important for people to decide whether to accept vaccines | Expressed hesitancy to receive COVID-19 vaccines |
|----------------------------------|---------------------------------------------------------------|-----------------------------------------|------------------------------------------|-----------------------------------------------|-------------------------------------------------|-----------------------------------------------|
| **Age group**                    |                                                               |                                         |                                          |                                               |                                                 |                                               |
| <30 years                        | 3975 (84.3)                                                   | 4114 (87.3)                            | 3858 (81.9)                              | 4196 (89.0)                                   | 3195 (67.8)                                      | 2372 (50.3)                                    |
| 31 to 45                         | 2392 (75.4)                                                  | 2505 (78.9)                            | 2109 (66.5)                              | 2441 (76.9)                                   | 1587 (50.0)                                      | 1680 (51.2)                                    |
| 46 to 60                         | 1372 (70.5)                                                  | 1430 (73.5)                            | 1230 (63.2)                              | 1399 (71.9)                                   | 881 (45.3)                                      | 1064 (54.7)                                    |
| 60+                              | 514 (79.6)                                                   | 523 (81.0)                             | 479 (74.1)                               | 538 (83.3)                                    | 313 (48.5)                                      | 419 (64.9)                                     |
| **Female**                       |                                                               |                                         |                                          |                                               |                                                 |                                               |
|                                  | 4482 (75.5)                                                  | 4682 (78.9)                            | 4151 (69.9)                              | 4727 (79.6)                                   | 3175 (53.5)                                      | 3112 (52.4)                                    |
| Urban residence                  |                                                               |                                         |                                          |                                               |                                                 |                                               |
|                                 | 6022 (81.2)                                                  | 6300 (85.0)                            | 5733 (77.3)                              | 6271 (84.6)                                   | 4492 (60.6)                                     | 3840 (51.8)                                    |
| **Level of education**           |                                                               |                                         |                                          |                                               |                                                 |                                               |
| < Secondary                      | 1864 (71.2)                                                  | 1861 (71.1)                            | 1685 (64.3)                              | 1936 (73.9)                                   | 1230 (47.0)                                     | 1546 (59.0)                                    |
| Secondary                        | 2239 (78.0)                                                  | 2281 (79.5)                            | 2107 (73.4)                              | 2265 (78.9)                                   | 1611 (56.1)                                     | 1471 (51.3)                                    |
| > Secondary                      | 4150 (83.2)                                                  | 4430 (88.8)                            | 3884 (77.9)                              | 4373 (87.7)                                   | 3135 (62.9)                                     | 2518 (50.5)                                    |
| **Currently employed**           |                                                               |                                         |                                          |                                               |                                                 |                                               |
|                                 | 5064 (75.6)                                                  | 5346 (79.9)                            | 4593 (68.6)                              | 5226 (78.1)                                   | 3388 (50.6)                                     | 3607 (53.9)                                    |
| Ever married                     | 4291 (76.6)                                                  | 4472 (79.8)                            | 3767 (67.2)                              | 4426 (79.0)                                   | 2726 (48.6)                                     | 3079 (54.9)                                    |
| **Family economic status**       |                                                               |                                         |                                          |                                               |                                                 |                                               |
| Low                              | 2285 (75.8)                                                  | 2360 (78.2)                            | 2242 (74.3)                              | 2436 (80.8)                                   | 1924 (63.8)                                     | 1624 (53.8)                                    |
| Medium                           | 3924 (79.5)                                                  | 4035 (81.8)                            | 3607 (73.1)                              | 4063 (82.4)                                   | 2789 (56.5)                                     | 2566 (52.0)                                    |
| High                             | 2044 (80.9)                                                  | 2177 (86.1)                            | 1827 (72.3)                              | 2075 (82.1)                                   | 1263 (50.0)                                     | 1345 (53.2)                                    |
| **Total**                        | 8253 (78.8)                                                  | 8572 (81.8)                            | 7676 (73.3)                              | 8574 (81.8)                                   | 5976 (57.0)                                     | 5535 (52.8)                                    |

** Significant at $P < 0.01$

https://doi.org/10.1371/journal.pntd.0010103.t002

As shown in Table 4, the levels of perceived COVID-19 vaccine effectiveness, acceptance, drivers of vaccine uptake decision-making, and vaccine uptake hesitancy remained significantly associated with the country of residence after controlling for socio-demographic and economic characteristics. For example, participants from Australia, Bangladesh, Indonesia, Iraq, Malaysia, Myanmar, the Philippines, Turkey, and Vietnam were significantly more likely to agree that vaccination would effectively control and prevent COVID-19 than participants from other countries. Compared to participants from other countries, participants from Bangladesh, Iraq, Malaysia, Myanmar, Thailand, Turkey, and Vietnam were significantly more likely to get the COVID-19 vaccines. Regarding hesitancy in vaccine uptake, participants from Austria, Indonesia, Iraq, Turkey, and Vietnam were significantly more likely to express their hesitancy to receive COVID-19 vaccines than participants from other countries.

The levels of perceived COVID-19 vaccine effectiveness, acceptance, drivers of vaccine uptake decision-making, and vaccine uptake hesitancy also remained significantly associated.
with socio-demographic and economic characteristics. For example, participants in the age groups of 31–45 years and 46–60 years were significantly less likely to agree that vaccination would effectively control and prevent COVID-19, accept the vaccines, and agree that convenience, health providers’ advice, and vaccine costs are important for deciding whether they would receive the vaccines relative to those who were 30 years or younger. Male participants were significantly more likely to agree that vaccination would effectively prevent and control COVID-19, accept the vaccines, and express their hesitancy to receive COVID-19 vaccines than female participants.

Urban participants were significantly more likely to agree that vaccination would effectively prevent and control COVID-19, accept the vaccines, and agree that convenience and health providers’ advice is important for deciding whether they would receive the vaccines. Compared to participants with education lower than secondary, participants with education higher than secondary level were significantly more likely to agree that vaccination would effectively prevent and control COVID-19; accept the vaccines; agree that convenience, health providers’ advice, and vaccine costs are important for deciding whether they would receive the vaccines; and express their hesitancy to receive COVID-19 vaccines.

Employed and never married participants were significantly more likely to express their hesitancy to receive COVID-19 vaccines than employed and ever married participants, respectively. Compared to low-economic families, participants from medium- and high-economic families were significantly more likely to agree that vaccination would effectively prevent and control COVID-19, vaccine acceptance, health providers’ advice is important, and less likely to agree that vaccine convenience, and costs are important for deciding whether they would receive the vaccines.

**Discussion**

This multi-country study assessed the prevalence and related factors of perceived effectiveness, acceptance, and potential drivers of people’s decision-making in COVID-19 vaccine uptake.
### Table 4. Factors related to perceived COVID-19 vaccine effectiveness, acceptance, and drivers of the uptake decision-making (n = 10477).

| Country      | Agreed that vaccines are effective to prevent and control COVID-19 | Would accept COVID-19 vaccines when available | Believed that convenience is important for people to decide whether to accept vaccines | Believed that healthcare providers’ advice is important for people to decide whether to accept vaccines | Believed that cost of the vaccines is important for people to decide whether to accept vaccines | Expired hesitancy to receive COVID-19 vaccines |
|--------------|---------------------------------------------------------------|---------------------------------------------|-------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|------------------------------------------------|
|              |                                                                 |                                             |                                                                                     |                                                                                                 |                                                                                                 |                                                 |
| Australia    | 2.83 (1.64–4.88)**                                             | 1.16 (0.72–1.86)                           | 2.12 (1.32–3.38)**                                                                  | 2.05 (1.22–3.44)**                                                                               | 1.93 (1.23–3.03)**                                                                               | 1.01 (0.65–1.57)                                |
| Austria      | 1.31 (0.92–1.85)                                               | 1.30 (0.91–1.86)                           | 0.80 (0.58–1.11)                                                                  | 0.81 (0.56–1.16)                                                                                 | 0.40 (0.28–0.56)**                                                                               | 1.78 (1.29–2.45)**                              |
| Bangladesh   | 1.67 (1.08–2.58)**                                             | 4.81 (2.78–8.31)**                         | 5.52 (3.43–8.89)**                                                                  | 3.02 (1.78–5.11)**                                                                               | 2.64 (1.78–3.91)**                                                                               | 0.98 (0.68–1.42)                                |
| Egypt        | 0.67 (0.47–0.96)**                                             | 1.34 (0.92–1.95)                           | 3.27 (2.29–4.69)**                                                                  | 2.06 (1.39–3.05)**                                                                               | 3.37 (2.39–4.76)**                                                                               | 0.38 (0.27–0.53)**                              |
| Indonesia    | 3.58 (2.35–5.45)**                                             | 1.47 (0.99–2.17)                           | 1.26 (0.87–1.81)                                                                  | 6.61 (4.04–10.83)**                                                                               | 0.65 (0.45–0.94)**                                                                               | 2.17 (1.51–3.11)**                              |
| Iraq         | 2.74 (1.88–3.99)**                                             | 6.65 (4.42–10.02)**                        | 2.83 (2.00–4.00)**                                                                  | 3.19 (2.15–4.73)**                                                                               | 0.64 (0.46–0.90)**                                                                               | 1.48 (1.06–2.06)**                              |
| Malaysia     | 7.57 (4.88–11.74)**                                           | 7.62 (4.88–11.89)**                        | 10.68 (7.04–16.19)**                                                                | 8.99 (5.51–14.66)**                                                                               | 8.25 (5.69–11.97)**                                                                               | 0.52 (0.37–0.72)**                              |
| Myanmar      | 1.91 (1.20–3.02)**                                             | 2.67 (1.60–4.45)**                         | 4.05 (2.57–6.38)**                                                                  | 1.82 (1.13–2.93)                                                                                 | 3.10 (2.08–4.63)**                                                                               | 1.32 (0.90–1.94)                                |
| Nigeria      | 1.66 (0.99–2.78)                                               | 1.37 (0.82–2.30)                           | 4.69 (2.74–8.01)**                                                                  | 2.21 (1.25–3.93)**                                                                               | 5.09 (3.19–8.13)**                                                                               | 0.44 (0.29–0.67)**                              |
| Philippines  | 3.11 (1.90–5.09)**                                             | 1.40 (0.89–2.21)                           | 6.77 (3.95–11.61)**                                                                | 3.33 (1.85–5.98)**                                                                               | 3.35 (2.18–5.15)**                                                                               | 0.46 (0.32–0.69)**                              |
| Thailand     | 1.05 (0.75–1.48)                                               | 1.62 (1.14–2.30)**                         | 1.26 (0.92–1.74)                                                                  | 1.31 (0.92–1.87)                                                                                 | 1.49 (1.08–2.05)                                                                                 | 0.58 (0.43–0.80)**                              |
| Turkey       | 2.16 (1.48–3.17)**                                             | 2.54 (1.72–3.75)**                         | 3.45 (2.40–4.96)**                                                                  | 1.49 (1.00–2.20)                                                                                 | 4.58 (3.21–6.55)**                                                                               | 2.82 (1.99–3.98)**                              |
| Vietnam      | 3.33 (2.21–5.02)**                                             | 4.03 (2.64–6.17)**                         | 0.60 (0.43–0.85)**                                                                  | 0.77 (0.52–1.13)                                                                                 | 0.19 (0.13–0.28)**                                                                               | 5.54 (3.80–8.07)**                              |
| Other        | R                                                             | R                                           | R                                                                                   | R                                                                                                 | R                                                                                                 | R                                              |
| countries    | R                                                             | R                                           | R                                                                                   | R                                                                                                 | R                                                                                                 | R                                              |
| Age group    |                                                                |                                             |                                                                                     |                                                                                                 |                                                                                                 |                                                 |
| <30 years    | R                                                             | R                                           | R                                                                                   | R                                                                                                 | R                                                                                                 | R                                              |
| 31 to 45 years| 0.66 (0.57–0.76)**                                             | 0.58 (0.50–0.68)**                         | 0.66 (0.57–0.75)**                                                                  | 0.54 (0.46–0.63)**                                                                               | 0.77 (0.68–0.88)**                                                                               | 0.93 (0.82–1.04)                                |
| 46 to 60 years| 0.61 (0.51–0.71)**                                             | 0.54 (0.45–0.64)**                         | 0.66 (0.57–0.77)**                                                                  | 0.49 (0.41–0.59)**                                                                               | 0.71 (0.61–0.82)**                                                                               | 0.95 (0.82–1.09)                                |
| 60+ years    | 0.82 (0.65–1.03)                                               | 0.74 (0.57–0.94)**                         | 0.85 (0.68–1.06)                                                                  | 0.86 (0.66–1.11)                                                                                 | 0.62 (0.50–0.76)**                                                                               | 1.15 (0.94–1.40)                                |
| Sex          |                                                                |                                             |                                                                                     |                                                                                                 |                                                                                                 |                                                 |
| Female       | R                                                             | R                                           | R                                                                                   | R                                                                                                 | R                                                                                                 | R                                              |
| Male         | 1.28 (1.15–1.43)**                                             | 1.16 (1.03–1.30)**                         | 1.09 (0.99–1.21)                                                                  | 1.09 (0.97–1.22)                                                                                 | 0.99 (0.90–1.09)                                                                                 | 1.21 (1.11–1.32)**                              |
| Residential area |                                                              |                                             |                                                                                     |                                                                                                 |                                                                                                 |                                                 |
| Rural        | R                                                             | R                                           | R                                                                                   | R                                                                                                 | R                                                                                                 | R                                              |
| Urban        | 1.35 (1.21–1.51)**                                             | 1.40 (1.25–1.57)**                         | 1.25 (1.12–1.39)**                                                                  | 1.17 (1.04–1.32)**                                                                               | 1.05 (0.95–1.17)                                                                               | 1.04 (0.95–1.15)                                |
| Education level |                                                              |                                             |                                                                                     |                                                                                                 |                                                                                                 |                                                 |
| < Secondary  | R                                                             | R                                           | R                                                                                   | R                                                                                                 | R                                                                                                 | R                                              |
| Secondary    | 1.53 (1.33–1.76)**                                             | 1.42 (1.23–1.64)**                         | 1.37 (1.20–1.56)**                                                                  | 1.08 (0.93–1.25)                                                                                 | 1.35 (1.19–1.54)**                                                                               | 1.12 (0.99–1.27)                                |
| > Secondary  | 1.85 (1.61–2.13)**                                             | 2.68 (2.31–3.11)**                         | 1.55 (1.36–1.77)**                                                                  | 2.31 (2.00–2.67)**                                                                               | 1.41 (1.23–1.61)**                                                                               | 1.18 (1.04–1.33)**                              |
| Employment status |                                      |                                             |                                                                                     |                                                                                                 |                                                                                                 |                                                 |
| Employed     | R                                                             | R                                           | R                                                                                   | R                                                                                                 | R                                                                                                 | R                                              |

(Continued)
among a large-scale population recruited from 20 countries across four continents involving different socioeconomic and cultural contexts. We found that 78.8% of the participants agreed that vaccination would effectively control and prevent COVID-19, and 81.8% would get the vaccines if they would become available in the future. The participants believed that convenience (73.3%), health providers’ advice (81.8%), and costs of vaccines (57.0%) are important for deciding whether they would receive the vaccines. Almost half (47.2%) expressed their hesitancy to be vaccinated. Levels of perceived effectiveness ranged from 67.8% in Egypt to 95.9% in Malaysia and acceptance from 64.7% in Australia to 96.0% in Malaysia. Perceived drivers of vaccination decision-making also varied by country, ranging from 49.7% in Austria to 95.7% in Malaysia for convenience, 16.0% in Vietnam to 91.3% in Malaysia for costs of vaccines, and 31.5% in Egypt to 86.0% in Vietnam for hesitancy in vaccine uptake.

The findings are comparable with other existing studies. China showed the highest level of tendency to take COVID-19 vaccines (91.3%), whereas the lowest level was found in Congo (27.7%) [28–30]. A survey conducted in nine LIMCs reported COVID-19 vaccine acceptance rates of 76.4% to 88.8% [31]. The rapid dissemination of COVID-19 related information and increased infections and deaths worldwide can explain the high rates of perceived COVID-19 vaccine effectiveness and acceptance. These evolvements may raise the consciousness and lead to positive attitudes regarding the COVID-19 vaccines. A recent study conducted in LIMCs found that COVID-19 vaccine acceptance was positively related to COVID-19 knowledge and worries and fears of the pandemic [32]. In this study, regression analyses showed that the levels of perceived COVID-19 vaccine effectiveness, acceptance, drivers of vaccine uptake decision-making, and vaccine uptake hesitancy are significantly associated with the country of residence and several other socio-demographic and economic characteristics.

Individuals in the age groups of 31 to 45 and 46 to 60 were significantly less likely to agree that vaccination would successfully control and prevent COVID-19 and get the vaccine, compared to those aged 30 years or younger. They were also significantly more likely to agree that convenience, health providers’ advice, and vaccine costs are essential for deciding whether

Table 4. (Continued)

| Unemployed/student | 1.06 (0.92–1.21) | 0.96 (0.83–1.11) | 1.00 (0.88–1.14) | 1.23 (1.06–1.42)** | 1.25 (1.10–1.40)** | 0.81 (0.72–0.90)**
|---------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| Marital status      |                  |                  |                  |                  |                  |                  |
| Ever married        | R                | R                | R                | R                | R                | R                |
| Never married       | 0.92 (0.82–1.03) | 0.87 (0.77–0.99)*| 1.14 (1.01–1.28)*| 0.81 (0.72–0.93)**| 1.05 (0.94–1.17) | 1.12 (1.01–1.24)*|
| Perceived family economic status |
| Low                 | R                | R                | R                | R                | R                | R                |
| Medium              | 1.17 (1.04–1.32)*| 1.12 (0.99–1.27) | 0.93 (0.83–1.05) | 1.18 (1.04–1.35)*| 0.76 (0.68–0.85)**| 0.82 (0.74–0.90)**|
| High                | 1.46 (1.25–1.70)**| 1.48 (1.25–1.75)**| 0.81 (0.70–0.94)**| 1.09 (0.93–1.28) | 0.47 (0.41–0.54)**| 0.90 (0.79–1.02) |

Other countries include Canada, China, Germany, India, Ireland, New Zealand, Scotland, Sri-Lanka, and the United Kingdom. Data were presents as adjusted odds ratio (confidence interval). R: Reference
* P<0.05
**P<0.01.

https://doi.org/10.1371/journal.pntd.0010103.t004
they would receive the vaccines. The existing literature also suggests that age was negatively correlated with the COVID-19 vaccine acceptance [33,34]. Similarly, youngers exhibited greater odds of COVID-19 vaccine acceptance compared to participants with older age in nine LIMCs [31]. This is conceivable because younger people are more exposed to information and engaged on online platforms such as the internet and social media. Therefore, they are more likely to stay updated on the latest information about the COVID-19 [35]. In contrast, most previous studies reported that older adults were more likely to get the COVID-19 vaccines than those in younger age groups [36–45]. A few other studies did not find significant relationships between age and COVID-19 vaccine acceptance [30,46,47].

Males had greater odds of perceived COVID-19 vaccine effectiveness and acceptance than females. Males were also more likely to agree that vaccination convenience and health providers’ advice were essential drivers of decision-making in COVID-19 vaccine uptake. These findings affirm previous studies that also reported a similar direction of association in terms of COVID-19 vaccine acceptance [30,36,37,39,40,42,44,45,47–53]. In addition, lower odds of willingness to be vaccinated were reported in females compared to males in a multi-country study conducted in nine LMICs [31]. Likewise, a previous study found an inverse association that females were more likely to express acceptance of COVID-19 vaccine than males [41]. However, multiple studies exhibited no relationships between sex and COVID-19 vaccine acceptance [33,38,43,54].

Perceived COVID-19 vaccine effectiveness and acceptance rates were higher among participants residing in urban areas than rural residents. Urbans were also significantly more likely to agree that vaccination convenience and health providers’ advice were essential drivers of decision-making in COVID-19 vaccine uptake. These findings corroborate previous studies that revealed the relationship between the increased willingness to take or accept COVID-19 vaccines among urban residents [39,42,51]. This association may be because urbans have a better COVID-19 prevention awareness than rural [55]. In contrast, another study found that participants from rural areas were more likely to express their tendency to receive COVID-19 vaccines than those in urban areas [31,33]. However, other studies did not find significant relationships [30,40,45].

Highly educated participants were more likely to perceive that COVID-19 vaccines would effectively control and prevent COVID-19 and accept them once available than those with lower education. In addition, they were more likely to believe that convenience, health providers’ advice, and vaccination costs are important drivers of people’s decision-making to receive the COVID-19 vaccines and express less hesitancy in its uptake. The findings are in line with previous studies showing that higher education is related to increased COVID-19 vaccine acceptance [33,42,56]. Similarly, another study in multiple LIMCs reported a positive relationship between education and COVID-19 vaccine acceptance [32]. Raising COVID-19 knowledge, particularly among lower-educated people, can effectively increase vaccine uptake [31]. However, this association was not detected in other studies [30,40,41,53,54].

Student or unemployed participants were more likely to believe that health providers’ advice and vaccination costs are important drivers of people’s decision-making to get the COVID-19 vaccines than employed participants. However, student or unemployed participants were less likely to express their hesitancy in the vaccine uptake. A study in England reported a positive association between employment and COVID-19 vaccine acceptance [46]. The relationship between education level and employment status can explain this finding. Employed people are more likely to have higher education and be aware of the COVID-19 pandemic and its prevention measures, including vaccination [57,58]. In contrast, a study in Israel found that unemployment was positively related to willingness to get COVID-19 vaccines and negatively associated with inoculation [59]. Other studies did not find relation between employment status and acceptance of COVID-19 vaccine [30,40,41,43,54].
In this study, never married respondents were more likely to believe that convenience is a crucial determinant of people’s decision-making to get the COVID-19 vaccines; whereas, ever married participants believed the healthcare workers’ advice. Never-married respondents were less likely to have vaccine acceptance, and more likely to have hesitancy in the vaccine uptake than ever-married respondents. This finding may indicate greater concern about COVID-19 among unmarried people. It may also be explained by the higher exposure to COVID-19 related information among younger groups as they tend to be more active in accessing information and social media [35]. This direction of the relation is in line with a previous study in Uganda [47] but inconsistent with other studies that reported married participants were more likely to express their intention to get the COVID-19 vaccines [30,38,54]. Some other studies did not find relation between marital status and acceptance of COVID-19 vaccine [40,53].

Participants from medium- and high-economic families were significantly more likely to agree that vaccination would effectively prevent and control COVID-19 than participants from low-economic families. They were less likely to agree that vaccine costs are important for deciding whether to receive the vaccines. The reduced COVID-19 vaccines acceptance rates among the low-income group may be due to scarcity of high-quality information and limited health literacy among lower-income individuals [60]. The present findings are partially supported by other studies that reported that income was positively related to the acceptance of the COVID-19 vaccines [40,42,46]. In contrast, a study in China did not find this relationship [30,40].

This multi-country survey is among a few studies exploring factors that may contribute to COVID-19 vaccine uptake improvement using extensive data collected from populations in countries with different socioeconomic and cultural contexts. However, this study has several limitations. Response biases could be one of the significant limitations because data were self-reported and collected through online platforms. The snowball technique used to recruit respondents could hamper the heterogeneity in the study sample. Another significant limitation is the study population representativeness that included a higher proportion of highly educated and urban samples more likely to access the online surveys. Moreover, the present study included the limited measures as it didn’t investigate any health literacy-related information.

In conclusion, most of the general adult population in this multi-country study believed vaccination would effectively control and prevent COVID-19. They would accept the vaccines when they become available. Perceived drivers of people’s vaccination decision-making included convenience, health providers’ advice, and vaccination costs. About half had been vaccinated or would accept the vaccination when the vaccines become available, while the other half expressed their hesitancy to be vaccinated. Several economic and socio-demographic factors are related to the perceived COVID-19 vaccine effectiveness, acceptance, and hesitancy in the populations. These factors are critical and should be considered as essential elements in developing COVID-19 vaccination programs to boost the vaccine uptake in the populations.

**Acknowledgments**

We would like to thank the participants of this study.

**Author Contributions**

**Conceptualization:** Roy Rillera Marzo.

**Data curation:** Roy Rillera Marzo, Absar Ahmad.

**Formal analysis:** Roy Rillera Marzo, Absar Ahmad.
Funding acquisition: Yulan Lin.

Investigation: Roy Rillera Marzo, Absar Ahmad, Md. Saiful Islam, Mohammad Yasir Essar, Petra Heidler, Isabel King, Arulmani Thiagarajan, Kittisak Jermsittiparsert, Karnjana Songwathana, Delan Ameen Younus, Radwa Abdullah El-Abasiri, Burcu Kucuk Bicer, Nhat Tan Pham, Titik Respati, Susan Fitriyana, Erwin Martínez Faller, Aries Moralidad Baldonado, Md Arif Billah, Yadanar Aung, Shehu Muhammad Hassan, Muhammad Mujtaba Asad, Kareem Ahmed El-Fass, Sudip Bhattacharya, Sunil Shrestha, Nouran Ameen Elsayed Hamza, Pascal Friedmann, Michael Head, Yulan Lin, Siyan Yi.

Methodology: Roy Rillera Marzo, Absar Ahmad, Md. Saiful Islam.

Project administration: Roy Rillera Marzo.

Software: Roy Rillera Marzo, Absar Ahmad.

Validation: Roy Rillera Marzo, Yulan Lin.

Visualization: Roy Rillera Marzo, Absar Ahmad, Md. Saiful Islam, Yulan Lin.

Writing – original draft: Roy Rillera Marzo, Md. Saiful Islam, Mohammad Yasir Essar, Yulan Lin.

Writing – review & editing: Roy Rillera Marzo, Absar Ahmad, Md. Saiful Islam, Mohammad Yasir Essar, Petra Heidler, Isabel King, Arulmani Thiagarajan, Kittisak Jermsittiparsert, Karnjana Songwathana, Delan Ameen Younus, Radwa Abdullah El-Abasiri, Burcu Kucuk Bicer, Nhat Tan Pham, Titik Respati, Susan Fitriyana, Erwin Martínez Faller, Aries Moralidad Baldonado, Md Arif Billah, Yadanar Aung, Shehu Muhammad Hassan, Muhammad Mujtaba Asad, Kareem Ahmed El-Fass, Sudip Bhattacharya, Sunil Shrestha, Nouran Ameen Elsayed Hamza, Pascal Friedmann, Michael Head, Yulan Lin, Siyan Yi.

References

1. Worldometers. Covid-19 Coronavirus Pandemic [cited 2021 September 6]. In: Worldometers [Internet]. Available from: https://www.worldometers.info/coronavirus/.

2. Shadmi E, Chen Y, Dourado I, Faran-Perach I, Furler J, Hangjima P, et al. Health equity and COVID-19: global perspectives. International Journal for Equity in Health. 2020; 19(1):104. https://doi.org/10.1186/s12939-020-01218-z PMID: 32586388; PubMed Central PMCID: PMC7165850.

3. Bong CL, Brasher C, Chi Kumba E, McDougall R, Mollin-Olsen J, Enright A. The COVID-19 Pandemic: Effects on Low- and Middle-Income Countries. Anesth Analg. 2020; 131(1):86–92. Epub 2020/04/04. https://doi.org/10.1213/ANE.0000000000001218 PMID: 32586388; PubMed Central PMCID: PMC7165850.

4. Hamid H, Abid Z, Amir A, Rehman TU, Akram W, Mehboob T. Current burden on healthcare systems in low- and middle-income countries: recommendations for emergency care of COVID-19. Drugs Ther Perspect. 2020; 1–3. Epub 2020/08/25. https://doi.org/10.1007/s40267-020-00766-2 PMID: 32837195; PubMed Central PMCID: PMC7173081.

5. Shrestha R, Shrestha S, Khanal P, Ko B. Nepal’s first case of COVID-19 and public health response. J Travel Med. 2020; 27(3). Epub 2020/02/28. https://doi.org/10.1093/jtm/taaa024 PMID: 32104884; PubMed Central PMCID: PMC710752.

6. Siddiqui AF, Wiederkehr M, Rozanova L, Fisha L. Situation of India in the COVID-19 Pandemic: India’s Initial Pandemic Experience. Int J Environ Res Public Health. 2020; 17(23). Epub 2020/12/06. https://doi.org/10.3390/ijerph17238994 PMID: 33276678; PubMed Central PMCID: PMC7703085.

7. Novelli G, Colona VL, Pandolfi PP. A focus on the spread of the delta variant of SARS-CoV-2 in India. Italian J Med Res. 2021. Epub 2021/07/15. https://doi.org/10.4103/ijmr.ijmr_1353_21 PMID: 34259195.

8. Sah R, Shrestha S, Mehta R, Sah SK, Rabaan AA, Dharma K, et al. AZD1222 (Covishield) vaccine for COVID-19: Experiences, challenges, and solutions in Nepal. Travel Med Infect Dis. 2021; 40:101999–. Epub 2021/02/10. https://doi.org/10.1016/j.tmaid.2021.101999 PMID: 33578045.

9. Sah R, Khatriwada AP, Shrestha S, Bhuvan KC, Tiwari R, Mohapatra RK, et al. COVID-19 vaccination campaign in Nepal, emerging UK variant and futuristic vaccination strategies to combat the ongoing
pandemic. Travel Med Infect Dis. 2021; 41:102037–. Epub 2021/03/27. https://doi.org/10.1016/j.tmaid.2021.102037 PMID: 33781945.

10. Excler J-L, Saville M, Berkley S, Kim JH. Vaccine development for emerging infectious diseases. Nature Medicine. 2021; 27(4):591–600. https://doi.org/10.1038/s41591-021-01301-0 PMID: 33846611.

11. Machingaidze S, Wyloonge CS. Understanding COVID-19 vaccine hesitancy. Nature Medicine. 2021; 27(8):1338–9. https://doi.org/10.1038/s41591-021-01459-7 PMID: 34272500.

12. Shrestha S, Khatri J, Shakya S, Danekhu K, Khatriwada AP, Sah R, et al. Adverse events related to COVID-19 vaccines: the need to strengthen pharmacovigilance monitoring systems. Drugs & Therapy Perspectives. 2021; 37(8):376–82. https://doi.org/10.1007/s40267-021-00852-z PMID: 34366660; PubMed Central PMCID: PMC8327058.

13. Peretti-Watel P, Larson HJ, Ward JK, Schulz WS, Verger P. Vaccine hesitancy: clarifying a theoretical framework for an ambiguous notion. PLoS Curr. 2015;7. Epub 2015/03/20. https://doi.org/10.1371/currents.outbreaks.6b44c80ff95b273f34c917f1b7fc289 PMID: 25789201; PubMed Central PMCID: PMC4353679.

14. MacDonald NE. Vaccine hesitancy: Definition, scope and determinants. Vaccine. 2015; 33(34):4161–4. https://doi.org/10.1016/j.vaccine.2015.04.036 PMID: 25896383.

15. Kumar D, Chandra R, Mathur M, Samdariya S, Kapoor N. Vaccine hesitancy: understanding better to address better. Isr J Health Policy Res. 2016; 5:2–. https://doi.org/10.1186/s13584-016-0062-y PMID: 26839681.

16. Soares P, Rocha JV, Moniz M, Gama A, Laires PA, Pedro AR, et al. Factors Associated with COVID-19 Vaccine Hesitancy. Vaccines. 2021; 9(3):300. PMID: https://doi.org/10.3390/vaccines9030300 PMID: 33810131

17. The Lancet Child & Adolescent Health. Vaccine hesitancy: a generation at risk. The Lancet Child & Adolescent Health. 2019; 3(5):281. https://doi.org/10.1016/S2352-4642(19)30092-6 PMID: 30981382.

18. World Health Organization. More than 140,000 die from measles as cases surge worldwide [cited 2021 September 1]. In: World Health Organization [Internet]. Available from: https://www.who.int/news/item/05-12-2019-more-than-140-000-die-from-measles-as-cases-surge-worldwide.

19. Khatiwada AP, Shakya S, Shrestha S. Paradigm shift of drug information centers during the COVID-19 pandemic. Drugs & Therapy Perspectives. 2020; 36(9):389–95. https://doi.org/10.1007/s10223-020-00075-3 PMID: 32837192; PubMed Central PMCID: PMC7370873.

20. Marzo RR, Ahmad A, Abid K, Khatiwada AP, Ahmed A, Kyaw TM, et al. Factors influencing the acceptability of COVID-19 vaccination: A cross-sectional study from Malaysia. Vaccines. 2021. https://doi.org/10.1016/j.vacun.2021.07.007 PMID: 34483788; PubMed Central PMCID: PMC8407955

21. Kalam MA, Davis TP Jr., Shano S, Uddin MN, Islam MA, Kanwagi R, et al. Exploring the behavioral determinants of COVID-19 vaccine acceptance among an urban population in Bangladesh: Implications for behavior change interventions. PLOS ONE. 2021; 16(8):e0256496. https://doi.org/10.1371/journal.pone.0256496 PMID: 34424913; PubMed Central PMCID: PMC8382171.

22. Soares P, Rocha JV, Moniz M, Gama A, Laires PA, Pedro AR, et al. Factors Associated with COVID-19 Vaccine Hesitancy. Vaccines. 2021; 9(3):300. PMID: https://doi.org/10.3390/vaccines9030300 PMID: 33810131

23. AI-Qerem WA, Jarab AS. COVId-19 Vaccination Acceptance and Its Associated Factors Among a Middle Eastern Population. Frontiers in Public Health. 2021; 9(34). https://doi.org/10.3389/fpubh.2021.632914 PMID: 33643995; PubMed Central PMCID: PMC7902782.

24. Harapan H, Wagner AL, Yufika A, Winardi W, Anwar S, Gan AK, et al. Acceptance of a COVID-19 Vaccine in Southeast Asia: A Cross-Sectional Study in Indonesia. Frontiers in Public Health. 2020; 8(381). https://doi.org/10.3389/fpubh.2020.00381 PMID: 32760691; PubMed Central PMCID: PMC7372105.

25. Nemat A, Bahez A, Salih M, Raufi N, Noor NAS, Essar MY, et al. Public Willingness and Hesitancy to Take the COVID-19 Vaccine in Afghanistan. Am J Trop Med Hyg. 2021. Epub 2021/07/09. https://doi.org/10.4269/ajtmh.21-0231 PMID: 34272499; PubMed Central PMCID: PMC8363502.

26. Al-Qerem WA, Jarab AS. COVID-19 Vaccination Acceptance and Its Associated Factors Among a Middle Eastern Population. Frontiers in Public Health. 2021; 9(34). https://doi.org/10.3389/fpubh.2021.632914 PMID: 33643995; PubMed Central PMCID: PMC7902782.

27. Wang J, Jing R, Lai X, Zhang H, Lyu Y, Knoll MD, et al. Acceptance of COVID-19 vaccination during the COVID-19 pandemic in China. Vaccines. 2020; 8(3):482–. https://doi.org/10.3390/vaccines8030482 PMID: 32867224; PubMed Central PMCID: PMC7565574.

28. Kabamba Nzaji M, Kabamba Ngombe L, Ngoie Mwamba G, Banza Ndana DB, Mbidi Miema J, Luhata Lungoyo C, et al. Acceptability of Vaccination Against COVID-19 Among Healthcare Workers in the
29. Wake AD. The Willingness to receive COVID-19 vaccine and its associated factors: “Vaccination refusal could prolong the war of this pandemic” — A systematic review. Risk management and healthcare policy. 2021; 14: 2609–23. https://doi.org/10.2147/PRM.S311074 PMID: 34188572; PubMed Central PMCID: PMC8232962.

30. Wang J, Jing R, Lai X, Zhang H, Lyu Y, Knoll MD, et al. Acceptance of COVID-19 Vaccination during the COVID-19 Pandemic in China. Vaccines (Basel). 2020; 8(3). Epub 2020/09/02. https://doi.org/10.3390/vaccines8030482 PMID: 32867224; PubMed Central PMCID: PMC7565574.

31. Bono SA, Faria de Moura Villela E, Siau CS, Chen WS, Pengpid S, Hasan MT, et al. Factors Affecting COVID-19 Vaccine Acceptance: An International Survey among Low- and Middle-Income Countries. Vaccines. 2021; 9(5):515. https://doi.org/10.3390/vaccines9050515 PMID: 34067682; PubMed Central PMCID: PMC8157062.

32. Bono SA, Faria de Moura Villela E, Siau CS, Chen WS, Pengpid S, Hasan MT, et al. Factors affecting COVID-19 vaccine acceptance: An international survey among low- and middle-income countries. Vaccines. 2021; 9(5). https://doi.org/10.3390/vaccines9050515 PMID: 34067682; PubMed Central PMCID: PMC8157062.

33. Gagneux-Brunon A, Detoc M, Bruel S, Tardy B, Rozaire O, Frappe P, et al. Intention to get vaccinations against COVID-19: a scoping review. Lancet Digit Health. 2021 Mar; 3(3):e175–e194. https://doi.org/10.1016/S2589-7500(20)30315-0 Epub 2021 Jan 28. PMID: 33518503; PubMed Central PMCID: PMC7906737.

34. Kourlaba G, Kourkouni E, Maistrelli S, Tsopela CG, Molocha NM, Triantafyllou C, et al. Willingness of Greek general population to get a COVID-19 vaccine. Glob Health Res Policy. 2021; 6(1):3. Epub 2021/01/30. https://doi.org/10.1186/s41256-021-00188-1 PMID: 33509291; PubMed Central PMCID: PMC8432420.

35. Kuter BJ, Browne S, Morplaisir FM, Feemster KA, Shen AK, Green-McKenzie J, et al. Perspectives on the receipt of a COVID-19 vaccine: A survey of employees in two large hospitals in Philadelphia. Vaccine. 2021; 39(12):1693–700. Epub 2021/02/27. https://doi.org/10.1016/j.vaccine.2021.02.029 PMID: 33632563; PubMed Central PMCID: PMC7885691.

36. Machida M, Nakamura I, Kojima T, Saito R, Nakaya T, Hanibuchi T, et al. Acceptance of a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic. Vaccine. 2020; 38(45):7002–6. https://doi.org/10.1016/j.vaccine.2020.09.041 PMID: 33388688; PubMed Central PMCID: PMC7498238.

37. Seale H, Heywood AE, Leask J, Sheel M, Durhneim DN, Bolswicz K, et al. Examining Australian public perceptions and behaviors towards a future COVID-19 vaccine. BMC Infectious Diseases. 2021; 21 (1):120. https://doi.org/10.1186/s12879-021-05833-1 PMID: 33509104; PubMed Central PMCID: PMC7840792.

38. Sherman SM, Smith LE, Sim J, Amlôt R, Cutts M, Dasch H, et al. COVID-19 vaccination intention in the UK: results from the COVID-19 vaccination acceptability study (CoVacS), a nationally representative cross-sectional survey. Hum Vacc Immunother. 2021; 17(6):1612–21. Epub 2020/11/27. https://doi.org/10.1080/21645515.2020.1846397 PMID: 3324386; PubMed Central PMCID: PMC8115754.

39. Unroe KT, Evans R, Weaver L, Rusyniak D, Blackburn J. Willingness of Long-Term Care Staff to Receive a COVID-19 Vaccine: A Single State Survey. J Am Geriatr Soc. 2021; 69(3):593–9. Epub 2020/12/29. https://doi.org/10.1111/jgs.17022 PMID: 33370448.
45. Yoda T, Katsuyma H. Willingness to Receive COVID-19 Vaccination in Japan. Vaccines (Basel). 2021; 9(1). Epub 2021/01/21. https://doi.org/10.3390/vaccines9010048 PMID: 33466675; PubMed Central PMCID: PMC7828811.

46. Bell S, Clarke R, Mounier-Jack S, Walker JL, Paterson P. Parents’ and guardians’ views on the acceptability of a future COVID-19 vaccine: A multi-methods study in England. Vaccine. 2020; 38(49):7789–98. Epub 2020/10/29. https://doi.org/10.1016/j.vaccine.2020.10.027 PMID: 33109389; PubMed Central PMCID: PMC7569401.

47. Kanyike AM, Olum R, Kajirima J, Ojjong D, Akech GM, Nassozi DR, et al. Acceptance of the coronavirus disease-2019 vaccine among medical students in Uganda. Trop Med Health. 2021; 49(1):37. Epub 2021/05/15. https://doi.org/10.1186/s41182-021-00331-1 PMID: 33985592; PubMed Central PMCID: PMC8116637.

48. Alqudeimat Y, Alenezi D, AlHajri B, Alfouzan H, Almokhaizeem Z, Altamimi S, et al. Acceptance of a COVID-19 Vaccine and its Related Determinants among the General Adult Population in Kuwait. Med Princ Pract. 2021; 30(3):262–71. Epub 2021/01/25. https://doi.org/10.1159/000514636 PMID: 33486492; PubMed Central PMCID: PMC8089409.

49. Malik AA, McFadden SM, Elharake J, Omer SB. Determinants of COVID-19 vaccine acceptance in the US. EClinicalMedicine. 2020; 26:100495. Epub 2020/08/25. https://doi.org/10.1016/j.eclinm.2020.10.027 PMID: 32838242; PubMed Central PMCID: PMC7423333.

50. Shaw J, Stewart T, Anderson KB, Hanley S, Thomas SJ, Salmon DA, et al. Assessment of U.S. health care personnel (HCP) attitudes towards COVID-19 vaccination in a large university health care system. Clin Infect Dis. 2021. Epub 2021/01/26. https://doi.org/10.1093/cid/ciab054 PMID: 33491049; PubMed Central PMCID: PMC7929026.

51. Urrunaga-Pastor D, Bendezu-Quispe G, Herrera-Añazco P, Uyen-Cateriano A, Toro-Huamanchumo CJ, Rodriguez-Morales AJ, et al. Cross-sectional analysis of COVID-19 vaccine intention, perceptions and hesitancy across Latin America and the Caribbean. Travel Med Infect Dis. 2021; 41:102059. Epub 2021/04/14. https://doi.org/10.1016/j.tmaid.2021.102059 PMID: 33848692; PubMed Central PMCID: PMC8063600.

52. Wong LP, Alias H, Wong PF, Lee HY, Abu Bakar S. The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay. Hum Vaccin Immunother. 2020; 16(9):2204–14. Epub 2020/07/31. https://doi.org/10.1080/21645515.2020.1790279 PMID: 32730103; PubMed Central PMCID: PMC7553708.

53. Tobin EA, Okonofua M, Adeke A, Obi A. Willingness to Accept a COVID-19 Vaccine in Nigeria: A Population-based Cross-sectional Study. Cent Afr J Public Health. 2021; 7(2):53.

54. Al-Mohaithef M, Padhi BK. Determinants of COVID-19 Vaccine Acceptance in Saudi Arabia: A Web-Based National Survey. J Multidiscip Healthc. 2020; 13:1657–63. Epub 2020/12/03. https://doi.org/10.2147/JMDH.S276771 PMID: 33262600; PubMed Central PMCID: PMC7686470.

55. Zhan S, Yang YY, Fu C. Public’s early response to the novel coronavirus-infected pneumonia. Emerg Microbes Infect. 2020; 9(1):534–. https://doi.org/10.1080/22221751.2020.1732232 PMID: 32122250; PubMed Central PMCID: PMC7067171.

56. Guidry JPD, Laestadius LI, Vraga EK, Miller CA, Perrin PB, Burton CW, et al. Willingness to get the COVID-19 vaccine with and without emergency use authorization. Am J Infect Control. 2021; 49(2):137–42. Epub 2020/11/24. https://doi.org/10.1016/j.ajic.2020.11.018 PMID: 33227323; PubMed Central PMCID: PMC6777682.

57. Ferdous MZ, Islam MS, Sikder MT, Mosaddek ASM, Zegarra-Valdivia JA, Gozal D. Knowledge, attitude, and practice regarding COVID-19 outbreak in Bangladesh: An online-based cross-sectional study. PLOS ONE. 2020; 15(10):e0239254. https://doi.org/10.1371/journal.pone.0239254 PMID: 33035219; PubMed Central PMCID: PMC7546509.

58. Islam MS, Siddique AB, Akter R, Tasnim R, Sujan MSH, Ward PR, et al. Knowledge, attitudes and perceptions towards COVID-19 vaccinations: a cross-sectional community survey in Bangladesh. BMC Public Health. 2021 Oct 13; 21(1):1851. https://doi.org/10.1186/s12889-021-11880-9 PMID: 34645399; PubMed Central PMCID: PMC8513387.

59. Zigron A, Dror AA, Morozov NG, Shani T, Haj Khalil T, Eisenbach N, et al. COVID-19 Vaccine Acceptance Among Dental Professionals Based on Employment Status During the Pandemic. Frontiers in Medicine. 2021; 8(13). https://doi.org/10.3389/fmed.2021.618403 PMID: 33634419; PubMed Central PMCID: PMC7901230.

60. Dash S, Parrey AA, De Freitas L, Mithu MIH, Rahman MM, Ramasamy A, et al. Combating the COVID-19 infodemic: a three-level approach for low and middle-income countries. BMJ Global Health. 2021; 6(1):e004671. https://doi.org/10.1136/bmjgh-2020-004671 PMID: 33514596; PubMed Central PMCID: PMC7849320.